title: Penetration of tacrine into cerebrospinal fluid in patients with Alzheimer's disease.
abstract: Tacrine is widely used for the treatment of Alzheimer's disease, but data are limited regarding cerebrospinal fluid (CSF) concentrations at steady state. To evaluate CSF penetration, seven patients with Alzheimer's disease who were receiving tacrine at doses of 40 to 140 mg/day as a part of a double-blind trial were studied. After 6 weeks of tacrine therapy, concomitant plasma and CSF samples were collected 30 minutes after the morning dose of tacrine. Although this time point is before the peak oral absorption in most patients, the critical issue for this study is that the plasma and CSF samples were collected concomitantly so that a percentage of tacrine penetration could be derived. The morning dose of tacrine ranged from 10 to 40 mg, which was given in the fasting state. Mean (+/-SD) plasma levels of tacrine were 8.01+/-7.07 ng/mL, whereas mean (+/-SD) CSF levels of tacrine were 5.21+/-6.00 ng/mL. The mean (+/-SD) ratio of CSF to plasma tacrine concentration was 0.50+/-0.45, with wide interindividual variability. No relationship between dose and percentage of penetration was observed. Plasma concentrations ranged from 0.99 to 22.6 ng/mL and were unrelated to dose, suggesting erratic oral absorption and/or rapid metabolism. CSF concentrations ranged from not detectable to 15.92 ng/mL. The authors support that penetration of tacrine into CSF is highly variable in patients with Alzheimer's disease and that disparity in tacrine concentrations at the site of action may be one reason for conflicting results from studies of the efficacy of tacrine in Alzheimer's disease.
authors.affiliation: Pharmacy Department, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892-1196, USA.
authors.forename: D R
authors.initials: DR
authors.lastname: Grothe
authors.forename: S C
authors.initials: SC
authors.lastname: Piscitelli
authors.forename: R
authors.initials: R
authors.lastname: Dukoff
authors.forename: T
authors.initials: T
authors.lastname: Fullerton
authors.forename: T
authors.initials: T
authors.lastname: Sunderland
authors.forename: S E
authors.initials: SE
authors.lastname: Molchan
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000097:blood / Q000134:cerebrospinal fluid*; D002800:Cholinesterase Inhibitors / Q000134:cerebrospinal fluid*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018697:Nootropic Agents / Q000134:cerebrospinal fluid*; D013619:Tacrine / Q000097:blood / Q000134:cerebrospinal fluid*
chemical_list: D002800:Cholinesterase Inhibitors; D018697:Nootropic Agents; D013619:Tacrine